secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2024-12-11T23:59:59+00:00
Accession:  0001104659-24-127439
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio enters $50M at-the-market equity distribution agreement with Oppenheimer
--------------------------------------------------------------------------------

- Agreement allows sale of up to $50M of common stock at-the-market through Oppenheimer & Co.
- Oppenheimer will receive 3.0% commission on gross proceeds; company also reimburses certain expenses.
- Company has no obligation to sell any shares and may suspend or terminate the agreement at any time.
- Shares will be issued under existing effective shelf registration statement (File No. 333-276814).
- Offering is effective December 11, 2024; sales subject to company instructions and market conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924127439/0001104659-24-127439-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924127439/tm2430444d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-127439

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer